Skip to main content
Switch to biosimilar referencing Humira is safe and effective, study shows
3/13/2018

Research in the Annals of the Rheumatic Diseases found no difference in efficacy, safety or immunogenicity when switching from Humira, or adalimumab, to the FDA-approved biosimilar Cyltezo, from Boehringer Ingelheim.

Full Story: